Managing menopausal symptoms after the women's health initiative

Journal of Midwifery and Women's Health

Volumn 49, Issue 2, 2004, Pages 87-95

  Hackley, Barbara ^a   Rousseau, Mary Ellen ^b  

^a Yale School of Nursing ^*  (United States)

^b YALE UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

Hormone replacement therapy; Hot flashes; Insomnia; Menopause; Urogenital atrophy

Indexed keywords

BELLADONNA ALKALOID; CALCIUM; CLONIDINE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTRIOL; ESTROGEN; ETHINYLESTRADIOL; FLUOXETINE; GESTAGEN; HERBACEOUS AGENT; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NORETHISTERONE ACETATE; PAROXETINE; PHENOBARBITAL; PLACEBO; PROGESTERONE; SERTRALINE; VALERIAN; VENLAFAXINE; VITAMIN D;

AGING; ARTICLE; BREAST CANCER; COLORECTAL CANCER; DEATH; DRUG ABSORPTION; DRUG MEGADOSE; DRUG SAFETY; ENDOMETRIUM CANCER; FEMALE; HIP FRACTURE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INSOMNIA; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SOYBEAN; STROKE; SYMPTOMATOLOGY; THROMBOEMBOLISM; URINARY TRACT DISEASE; VAGINA ATROPHY; VAGINA RING; VAGINAL DRYNESS; AGED; BREAST TUMOR; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; ESTROGEN THERAPY; MENOPAUSE; MIDDLE AGED; PHYSIOLOGY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SAFETY; STANDARD; URINE INCONTINENCE; VAGINA DISEASE;

AGED; AGING; BREAST NEOPLASMS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; SAFETY; SLEEP INITIATION AND MAINTENANCE DISORDERS; URINARY INCONTINENCE; VAGINAL DISEASES;

EID: 1542274583     PISSN: 15269523     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmwh.2003.12.005     Document Type: Article

References (74)

1. Brett K. Madans J. Use of postmenopausal hormone replacement therapy: Estimates from a nationally representative cohort study Am J Epidemiol 145 1997 536-545
2. Fletcher S. Colditz G. Failure of estrogen plus progestin therapy for prevention JAMA 288 2002 366-367
3. Austin P. Mamdani M. Tu K. Jaakkimainen L. Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative Study JAMA 289 2003 3241-3242
4. Rousseau M.E. Hormone replacement therapy: Short-term versus long-term use J Midwifery Womens Health 47 2002 461-470
5. Andersen L.F. Gram J. Skouby S.O. Jespersen J. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors Am J Obstet Gynecol 180 1999 283-289
6. Kamali P. Muller T. Lang U. Clapp J. Cardiovascular responses of perimenopausal women to hormonal replacement therapy Am J Obstet Gynecol 182 2000 17-22
7. The Writing Group for the PEPI Trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial JAMA 273 1995 199-208
8. Mosca L. Manson J.E. Sutherland S.E. Langer R. Manolio T. Barrett-Connor E.C. Cardiovascular disease in women: A statement for health care professionals from the American Heart Association Circulation 96 1997 2468-2482
9. Hulley S. Grady D. Bush T. Furberg D. Herrington D. Riggs B. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group JAMA 280 1998 605-613
10. Hulley S. Furberg C. Barrett-Connor E. Cauley J. Grady D. Haskell W. et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study (HERS 11) JAMA 288 2002 58-66
11. Mosca L. Collins P. Herrington D. Mendelsohn M. Pasternak R. Robertson R.M. et al. Hormone replacement therapy and cardiovascular disease: A statement for health professionals from the American Heart Association Circulation 104 2001 499-503
12. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial JAMA 288 2002 321-333
13. Grodstein F. Mason J. Stampfer M. Postmenopausal hormone use and secondary prevention of coronary events in the Nurse's Health Study Ann Intern Med 2001 2001 1-8
14. North American Menopause Society Role of progestogen in hormone therapy for postmenopausal women: Position statement of the North American Menopause Society Menopause 10 2003 113-132
15. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: Recommendations and rationale Ann Intern Med 137 2002 834-839
16. Grady D. Postmenopausal hormones - Therapy for symptoms only N Engl J Med 348 2003 1835-1837
17. Bachmann G. Vasomotor flushes in menopausal women Am J Obstet Gynecol 180 1999 S312-s316
18. Polo-Kantola P. Errkola R. Irjala K. Effect of short-term transdermal estrogen replacement therapy on sleep: A randomized, double-blind crossover trial in post menopausal women Fertil Steril 71 1999 873-880
19. McNagny S. Prescribing hormone replacement therapy for menopausal symptoms Ann Intern Med 131 1999 605-616
20. American College of Obstetricians and Gynecologists Hormone replacement therapy: ACOG Technical Bulletin Number 166-April 1992 Int J Gynecol Obstet 41 1993 194-202
21. Sloan J. Loprinzi C. Novotny P. Barton D. Lavasseur B. Windschitl H. Methodologic lessons learned from hot flash studies J Clin Oncol 19 2001 4280-4290
22. Many menopausal women using complementary therapies for symptoms Anonymous Reuters Medical News 2000 [cited Nov 6, 2000]. Available from: http://womenshealth.medscape.com/reuters/prof/2000/10/10.3/ 20001027epid02.html.
23. Greendale G. Reboussin B. Hogan P. Barnabei V. Shumaker S. Johnson S. et al. Symptom relief and side effects of postmenopausal hormones: Results from the Postmenopausal Estrogen/Progestin Intervention Trial Obstet Gynecol 92 1998 982-988
24. Utian W. Burry K. Archer D. Gallagher J. Boyett R. Guy M. et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients Am J Obstet Gynecol 181 1999 71-79
25. Nash H. Alvarez-Sanchez F. Mishell D. Fraser I. Maruo T. Harmon T. Estradiol-delivering vaginal rings for hormone replacement therapy Am J Obstet Gynecol 181 1999 1400-1406
26. Shanafelt T. Barton D. Adjei A. Loprinzi C. Pathophysiology and treatment of hot flashes Mayo Clin Proc 77 2002 1207-1218
27. Utian W. Shoupe D. Bachmann G. Pinkerton J. Pickar J. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate Fertil Steril 75 2001 1065-1079
28. Speroff L. Symons J. Kempfer N. Rowan J. Investigators F.S. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms Menopause 7 2000 383-390
29. Gambrell D. Progesterone skin cream and measurements of absorption Menopause 10 2003 1-5
30. Loprinzi C. Michalak J. Quella S. O'Fallon J. Hatfield A. Nelimark R. et al. Megestrol acetate for the prevention of hot flashes N Engl J Med 331 1994 347-352
31. Eden J. Progestins and breast cancer Am J Obstet Gynecol 188 2003 1123-1131
32. Loprinzi C. Pisansky T. Fonseca R. Sloan J. Zahasky K. Quella S. et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors J Clin Oncol 16 1998 2377-2381
33. Loprinzi C. Kugler J. Sloan J. Mailliard J. LaVasseur B. Barton D. et al. Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial Lancet 356 2000 2059-2063
34. Stearns V. Isaacs C. Rowland J. Crawford J. Ellis M. Kramer R. et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil®) in controlling hot flashes in breast cancer survivors Ann Oncol 11 2000 17-22
35. Stearns V. Beebe K. Iyengar M. Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: A randomized controlled trial JAMA 289 2003 2827-2834
36. Loprinzi C. Sloan J. Perez E. Quella S. Stella P. Mailliard J. et al. Phase 3 evaluation of fluoxetine for treatment of hot flashes J Clin Oncol 20 2002 1578-1583
37. Stearns V. Hayes D. Cooling off hot flashes J Clin Oncol 20 2002 1436-1438
38. Barton D. Loprinzi C. Quella S. Sloan J. Veeder M. Egner J. et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors J Clin Oncol 16 1998 495-500
39. Albertazzia P. Pansinia F. Bonaccorsia G. Zanottia L. Forinia E. De Aloysioa D. The effect of dietary soy supplementation on hot flushes Obstet Gynecol 91 1998 6-11
40. Scambia G. Mango D. Signorile P. Anselmi A. Palena C. Gallo D. et al. Clinical effects of a standardized soy extract in postmenopausal women: A pilot study Menopause 7 2000 76-77
41. Faure E. Chantre P. Mares P. Effects of a standardized soy extract on hot flushes: A multicenter, double-blind, randomized, placebo-controlled study Menopause 9 2002 329-334
42. Taylor M. Botanicals: Medicines and menopause Clin Obstet Gynecol 44 2001 853-863
43. St. Germain A. Peterson C. Robinson J. Alekel D.L. Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment Menopause 8 2001 17-26
44. Quella S.K. Loprinzi C.L. Barton D.L. Knost J.A. LaVasseur B.I. Swan D. Krupp K.R. Miller K.D. Novotny P.J. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial J Clin Oncol 18 2000 1068-1074
45. Van Patten C. Olivotto I. Chambers G. Gelmon K. Hislop T. Templeton E. et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: A randomized, controlled clinical trial Clin Oncol 20 2002 1449-1455
46. Jacobson J. Troxel A. Evans J. Klaus L. Vahdat L. Kinne D. et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer J Clin Oncol 19 2001 2739-2745
47. Wijma K. Melin A. Nedstrand E. Hammar M. Treatment of menopausal symptoms with applied relaxation: A pilot study J Behav Ther Exp Psychiatry 28 1997 251-261
48. Polo-Kantola P. Erkkola R. Helenius H. Irjala K. Polo O. When does estrogen replacement therapy improve sleep quality? Am J Obstet Gynecol 178 1998 1002-1009
49. Larzelere M. Wiseman P. Anxiety, depression, and insomnia Prim Care Clin Office Pract 29 2002 339-360
50. Arnulf I. Quintin P. Alvarez J. Vigil L. Touitou Y. Lebre A. et al. Mid-morning tryptophan depletion delays REM sleep onset in healthy subjects Neuropsychopharmacology 27 2002 843-851
51. Riemann D. Feige B. Hornyak M. Koch S. Hohagen F. Voderholzer U. The tryptophan depletion test: Impact on sleep in primary insomnia - A pilot study Psychiatry Res 109 2002 129-135
52. Cardazo L. Bachmann G. McClish D. Fonda D. Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second Report of the Hormones and Urogenital Therapy Committee Obstet Gynecol 92 1998 722-727
53. Willhite L. O'Connell M.B. Urogenital atrophy: Prevention and treatment Pharmacotherapy 21 2001 464-480
54. Bachmann G. The estradiol vaginal ring - A study of existing clinical data Maturitas 22 1995 S21-s29
55. Santen R. Pinkerton J. Conaway M. Roopka M. Wisniewshi L. Demers L. et al. Treatment of urogenital atrophy with low dose estradiol: Preliminary results Menopause 9 2002 179-187
56. McKenna S. Whalley D. Renck-Hooper U. Carlin S. Doward L. The development of a quality of life instrument for use with post-menopausal women with urogenital atrophy in the UK and Sweden Qual Life Res 8 1999 393-398
57. van der Laak J. de Bie L. de Leeuw H. de Wilde P. Hanselaar A. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: Cytomorphology versus computerised cytometry J Clin Pathol 55 2002 446-451
58. Bygdeman M. Swahn M. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women Maturitas 23 1996 259-263
59. Nachtigall L. Comparative study: Replens versus local estrogen in menopausal women Fertil Steril 61 1994 178-180
60. Loprinzi C. Abu-Ghazaleh S. Sloan J. van Haelst-Pisani C. Hammer A. Rowland K. et al. Phase 3 randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer J Clin Oncol 15 1997 969-973
61. Wilson P. Faragher B. Butler B. Bullock D. Robinson E. Brown A. Treatment with oral peperazine oestrone sulphate for genuine stress incontinence in postmenopausal women Br J Obstet Gynaecol 94 1987 568
62. Bhatia N. Bergman A. Karram M. Effects of estrogen on urethral function in women with urinary incontinence Obstet Gynecol 160 1989 176
63. Grady D. Brown J. Vittinghoff E. Applegate W. Varner E. Snyder T. Postmenopausal hormones and incontinence: The heart and estrogen/progestin replacement study Obstet Gynecol 97 2001 116-120
64. Al-Badr A. Ross S. Soroka D. Drutz H. What is the available evidence for hormone replacement therapy in women with stress urinary incontinence? J Obstet Gynaecol Can 25 2003 567-574
65. Thom D. Brown J. Reproductive and hormonal risk factors for urinary incontinence in later life: A review of the clinical and epidemiologic literature J Am Geriatr Soc 46 1998 1411-1417
66. Cicinelli E. Di Naro E. De Ziegleer D. Matteo M. Morgese S. Galantino P. et al. Placement of the vaginal 17 beta estradiol tablets in the inner or outer one third of the vagina affects the preferential delivery of 17 beta estradiol toward the uterus or periurethral areas, thereby modifying efficacy and endometrial safety Am J Obstet Gynecol 189 2003 55-58
67. Subak L. Quesenberry C. Posner S. Cattolica E. Soghikian K. The effect of behavioral therapy on urinary incontinence: A randomized controlled trial Obstet Gynecol 100 2002 72-78
68. Chen C.-L. Weiss N. Newcomb P. Barlow W. White E. Hormone replacement therapy in relation to breast cancer JAMA 287 2002 734-741
69. Doren M. Hormonal replacement regimens and bleeding Maturitas 34 2000 S17-S23
70. Ettinger B. Pressman A. Van Gessel A. Low-dosage esterified estrogens opposed by progestin at 6 month intervals Obstet Gynecol 98 2001 205-211
71. Naftolin F. Silver D. Is progestogen supplementation of ERT really necessary? Menopause 9 2002 1-2
72. Mattox J. Shulman L. Combined oral hormone replacement therapy formulations Am J Obstet Gynecol 185 2001 S38-S46
73. Cummings J. Brizendine L. Comparison of physical and emotional side effects of progesterone or medroxyporgesterone in early postmenopausal women Menopause 9 2002 253-263
74. Ishiko O. Hirai K. Sumi T. Tatsuta I. Ogita S. Hormone replacement therapy plus pelvic floor muscle exercise for postmenopausal stress incontinence: A randomized controlled trial J Reprod Med 46 2001 213-220